Related Experiment Videos
Chemotherapy for metastatic bladder cancer.
1Northern Centre for Cancer Treatment, Newcastle General Hospital, Newcastle upon Tyne, UK. trevor.roberts@nuth.nhs.uk
Clinical Oncology (Royal College of Radiologists (Great Britain))
|October 22, 2005
Summary
Systemic chemotherapy offers treatment options for advanced urothelial cancer, including survival benefits and roles before surgery. Research explores prognostic factors and future targeted therapies for better patient outcomes.
Area of Science:
- Oncology
- Urology
Background:
- Advanced and metastatic urothelial cancer presents significant treatment challenges.
- Systemic chemotherapy is a cornerstone in managing this disease, but optimal strategies are evolving.
Purpose of the Study:
- To review the current landscape of systemic chemotherapy for advanced urothelial cancer.
- To evaluate single agents, combination regimens, and prognostic factors influencing response and survival.
Main Methods:
- Review of existing literature on systemic chemotherapy in urothelial cancer.
- Analysis of randomized-controlled studies, prognostic factor data, and treatment strategies for specific patient groups.
Main Results:
- Various single agents and combination regimens show activity in advanced urothelial cancer.
- Prognostic factors impact response and long-term survival, with chemotherapy playing a role in neoadjuvant settings.
Conclusions:
- Systemic chemotherapy is integral to managing advanced urothelial cancer, offering survival benefits and neoadjuvant options.
- Future research should focus on molecular phenotyping and targeted therapies for improved treatment efficacy.